Moderna's RSV Vaccine for Seniors Gains FDA Approval

Moderna's stock fell after the FDA approved its second product, an RSV vaccine named mResvia, which targets respiratory syncytial virus in older adults. This approval further validates Moderna's mRNA technology, also used in its Covid vaccine. Despite the stock dip, analysts project significant future sales growth for the RSV vaccine, potentially giving Moderna an edge over competitors Pfizer and GSK. Moderna's pre-filled syringe for the vaccine could simplify administration in pharmacies, enhancing its market position.